Delineating the clinical value of MMF for joint manifestations
Comment on: Five-years drug survival of mycophenolate mofetil therapy in patients with systemic lupus erythematosus: comparison between renal and non-renal involvement. Joint Bone Spine 2021 Jun 22;105246. doi: 10.1016/j.jbspin.2021.105246. Online ahead of print Commented by: Thomas Dörner, Department of Medicine/Rheumatology and Clinical Immunology; Charite Universitätsmedizin Berlin, Germany While MMF has not been approved for SLE, … Read more
